期刊文献+

直肠恶性黑色素瘤术后复发乳腺转移1例报道 被引量:2

下载PDF
导出
摘要 恶性黑色素瘤是临床上较为常见的皮肤黏膜和色素膜恶性肿瘤,也是发病率增长最快的恶性肿瘤之一,年增长率为3%~5%。多发生于皮肤和眼睛,原发肛管直肠少见,是一种少见且预后极差的恶性肿瘤,
出处 《实用肿瘤杂志》 CAS 2013年第1期85-86,共2页 Journal of Practical Oncology
  • 相关文献

参考文献13

  • 1Pessaux P,Pllcard M, Elias D,el al. Surgical nlanagemenI of primary anorectal melanomal [ J ]. Br J Surg, 2004,91 (9) :1183 - 1187.
  • 2魏振海.乳腺转移性恶性黑色素瘤1例[J].中国厂矿医学,2008,21(4):392-392. 被引量:5
  • 3武忠弼 杨光华主编.中华外科病理学[M].北京:人民卫生出版社,2002.646.
  • 4同济医科大学病理教研室,中山医科大学病理教研室.外科病理学[M].武汉:湖北科学技术出版社.1983.494.
  • 5Lens MB, Dawes M. Global perspectives of contemporary epdemlemiological trends of cutaneous malignant melanoma [ J ]. Br J Dermato1,2004,150( 2 ) : 179 - 185.
  • 6Clenlente-Ruiz de Ahniron A, Sen'ano-Ollega S. Risk factors for in-transit metastasis in patients with cutaneous melanoma [ J ]. Acta Dermosifiliogr, 2012,103 ( 3 ) : 207 - 213.
  • 7Moore DA, Howard Pringle J, Saldanha GS. Prognostic tissue markers in melanoma[ J ]. Histopathology,2011,22 ( 1 ) :365-369.
  • 8Yee VS, Thompson JF, Mckinnnn JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative senlinel node biopsy [ J ]. Ann Surg Onco1,2005,12 ( 2 ) :429 - 439.
  • 9Thompson JF, Soong S J, Balch CM, et a]. Prognostic significance of mitotic rate in localized primary cutaneous melanoma:an analysis of patients in the muhi-institutional american joint committee on can(?er melanoma staging database[ J ]. Clin On('ol,2011,29(16) :2199 - 2205.
  • 10Woodman SE, Lazar AJ,Aldape KD, el al. New strategies in melanoma : molecular testing in advanced disease[ J ]. Clin Cancer Res,2012,24(2) :210 -218.

二级参考文献33

  • 1刘佳,周麟,侯梅.干扰素α在恶性黑色素瘤术后患者治疗中的研究进展[J].华西医学,2006,21(2):429-430. 被引量:3
  • 2刘勇,岑瑛,许学文,李正勇.236例皮肤恶性肿瘤临床分析[J].华西医学,2007,22(2):368-369. 被引量:15
  • 3武忠弼 杨光华主编.中华外科病理学[M].北京:人民卫生出版社,2002.646.
  • 4同济医科大学病理教研室,中山医科大学病理教研室.外科病理学[M].武汉:湖北科学技术出版社.1983.494.
  • 5Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma[J]. Br J Dermatol, 2004, 150(2): 179-185.
  • 6Hünig T, Dennehy K. CD28 superagonists: mode of action and therapeutic potential[J]. Immunol Lett, 2005, 100(1): 21-28.
  • 7Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator[J]. Immunity, 1997, 7(4): 445-450.
  • 8Kirkwood JM, Tarhini AA, Panelli MC, et al. Next Generation of immunotherapy for melanoma[J]. J Clin Oncol, 2008, 26(20): 3445-3455.
  • 9Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement[J]. Immunity, 1997, 6(4): 411-417.
  • 10Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4[J]. Science, 1995, 270(5238): 985-985.

共引文献551

同被引文献13

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部